MicroRNA gene methylation landscape in pediatric B-cell precursor acute lymphoblastic leukemia.


Journal

Advances in clinical and experimental medicine : official organ Wroclaw Medical University
ISSN: 1899-5276
Titre abrégé: Adv Clin Exp Med
Pays: Poland
ID NLM: 101138582

Informations de publication

Date de publication:
Mar 2022
Historique:
pubmed: 30 1 2022
medline: 2 4 2022
entrez: 29 1 2022
Statut: ppublish

Résumé

Aberrant DNA methylation is an important mechanism by which the normal patterns of microRNA expression are disrupted in human cancers including B-cell precursor acute lymphoblastic leukemia (BCP ALL), the most common pediatric malignancy. To characterize the methylation profile landscape of microRNA genes in BCP ALL patients. We employed Infinium® MethylationEPIC BeadChip Arrays to measure the methylation of microRNA genes from bone marrow samples of children with BCP ALL (n = 38) and controls without neoplasms (n = 4). This analysis revealed differential methylation of the microRNA genes in the pediatric BCP ALL when compared to the control. A subcluster amongst BCP ALL patients with TCF3-PBX1 genetic subtype was also observed. No other differences were observed in association with age, gender or risk group. Several interesting leukemia-related phenotypes are enriched by the genes with hyperand hypomethylated sites located in promoters as well as gene bodies. The top 3 miRNA genes, promoters of which were the most statistically significantly hypermethylated in BCP ALL were MIR1273G, MIR1304 and MIR663, and the top 3 hypomethylated were MIR4442, MIR155 and MIR3909. In this study, a different microRNA genes methylation landscape was shown in pediatric BCP ALL compared to children without neoplasms. A visible subcluster among BCP ALL samples consisted of individuals with TCF3-PBX1 genetic subtype. No other differences were observed in association with age, gender or risk group. Several interesting leukemia-connected phenotypes were found, associated with genes with hyperand hypomethylated sites located on promoters as well as gene bodies.

Sections du résumé

BACKGROUND BACKGROUND
Aberrant DNA methylation is an important mechanism by which the normal patterns of microRNA expression are disrupted in human cancers including B-cell precursor acute lymphoblastic leukemia (BCP ALL), the most common pediatric malignancy.
OBJECTIVES OBJECTIVE
To characterize the methylation profile landscape of microRNA genes in BCP ALL patients.
MATERIAL AND METHODS METHODS
We employed Infinium® MethylationEPIC BeadChip Arrays to measure the methylation of microRNA genes from bone marrow samples of children with BCP ALL (n = 38) and controls without neoplasms (n = 4).
RESULTS RESULTS
This analysis revealed differential methylation of the microRNA genes in the pediatric BCP ALL when compared to the control. A subcluster amongst BCP ALL patients with TCF3-PBX1 genetic subtype was also observed. No other differences were observed in association with age, gender or risk group. Several interesting leukemia-related phenotypes are enriched by the genes with hyperand hypomethylated sites located in promoters as well as gene bodies. The top 3 miRNA genes, promoters of which were the most statistically significantly hypermethylated in BCP ALL were MIR1273G, MIR1304 and MIR663, and the top 3 hypomethylated were MIR4442, MIR155 and MIR3909.
CONCLUSIONS CONCLUSIONS
In this study, a different microRNA genes methylation landscape was shown in pediatric BCP ALL compared to children without neoplasms. A visible subcluster among BCP ALL samples consisted of individuals with TCF3-PBX1 genetic subtype. No other differences were observed in association with age, gender or risk group. Several interesting leukemia-connected phenotypes were found, associated with genes with hyperand hypomethylated sites located on promoters as well as gene bodies.

Identifiants

pubmed: 35092653
doi: 10.17219/acem/144170
doi:

Substances chimiques

MIRN663 microRNA, human 0
MicroRNAs 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

293-305

Auteurs

Radosław Chaber (R)

Institute of Medical Sciences, Medical College of Rzeszów University, Poland.
Clinic of Pediatric Oncology and Hematology, State Hospital 2, Rzeszów, Poland.

Artur Gurgul (A)

Center for Experimental and Innovative Medicine, University of Agriculture in Krakow, Poland.

Jacek Tabarkiewicz (J)

Institute of Medical Sciences, Medical College of Rzeszów University, Poland.
Laboratory of Translational Research in Medicine, Centre for Innovative Research in Medical and Natural Sciences, Medical College of Rzeszów University, Poland.

Grażyna Wróbel (G)

Department of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, Poland.

Tomasz Szmatoła (T)

Center for Experimental and Innovative Medicine, University of Agriculture in Krakow, Poland.

Igor Jasielczuk (I)

Center for Experimental and Innovative Medicine, University of Agriculture in Krakow, Poland.

Olga Haus (O)

Department of Clinical Genetics, Faculty of Medicine, Collegium Medicum, Nicolaus Copernicus University, Toruń, Poland.

Monika Lejman (M)

Laboratory of Genetic Diagnostics, Medical University of Lublin, Poland.

Blanka Rybka (B)

Department of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, Poland.

Renata Ryczan-Krawczyk (R)

Department of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, Poland.

Anna Jaśkowiec (A)

Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Poland.

Sylwia Paszek (S)

Laboratory of Molecular Biology, Centre for Innovative Research in Medical and Natural Sciences, Medical College of Rzeszów University, Poland.

Natalia Potocka (N)

Laboratory of Molecular Biology, Centre for Innovative Research in Medical and Natural Sciences, Medical College of Rzeszów University, Poland.

Christopher J Arthur (CJ)

School of Chemistry, University of Bristol, the United Kingdom.

Wioletta Bal (W)

Institute of Medical Sciences, Medical College of Rzeszów University, Poland.
Clinic of Pediatric Oncology and Hematology, State Hospital 2, Rzeszów, Poland.

Kornelia Łach (K)

Institute of Medical Sciences, Medical College of Rzeszów University, Poland.

Aneta Kowal (A)

Institute of Medical Sciences, Medical College of Rzeszów University, Poland.

Izabela Zawlik (I)

Institute of Medical Sciences, Medical College of Rzeszów University, Poland.
Laboratory of Molecular Biology, Centre for Innovative Research in Medical and Natural Sciences, Medical College of Rzeszów University, Poland.

Elżbieta Latos-Grażyńska (E)

Department of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH